Sionna Therapeutics (SION) Accumulated Expenses (2024 - 2026)

Sionna Therapeutics has disclosed Accumulated Expenses across 3 years of filings, most recently posting $6.3 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $6.3 million, up 86.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.3 million (up 86.72% YoY), and the FY2025 annual result was $9.7 million, up 18.45% from the prior year.
• Accumulated Expenses came in at $6.3 million for Q1 2026 at Sionna Therapeutics, down from $9.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9.7 million in Q4 2025 to a low of $3.4 million in Q1 2025.
• The 3-year median for Accumulated Expenses is $6.6 million (2025), against an average of $6.7 million.
• Across the five-year window, Accumulated Expenses increased 18.45% in 2025 and soared 86.72% in 2026, its largest moves.
• Sionna Therapeutics' Accumulated Expenses stood at $8.2 million in 2024, then climbed by 18.45% to $9.7 million in 2025, then slumped by 34.55% to $6.3 million in 2026.
• The last three Accumulated Expenses figures came in at $6.3 million (Q1 2026), $9.7 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.